374 related articles for article (PubMed ID: 27749412)
41. PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
Crocerossa F; Carbonara U; Parekh J; Urdaneta A; Weprin S; Damiano R; Grob MB; Hampton LJ; Paul A; Autorino R; Cantiello F
Urol Int; 2022; 106(9):920-927. PubMed ID: 34933313
[TBL] [Abstract][Full Text] [Related]
42. Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.
Farkas AB; Green ED; Thaggard AL; Vijayakumar V; Henegan JC; Lirette ST; Nittala MR; Vijayakumar S
South Med J; 2021 Nov; 114(11):703-707. PubMed ID: 34729614
[TBL] [Abstract][Full Text] [Related]
43. Utility of
Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J
AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718
[No Abstract] [Full Text] [Related]
44. ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer.
Savir-Baruch B; Banks KP; McConathy JE; Molchanova-Cook OP; Parent EE; Takalkar A; Tulchinsky M; Yu JQ; Subramaniam RM; Schuster DM
Clin Nucl Med; 2018 Dec; 43(12):909-917. PubMed ID: 30325827
[TBL] [Abstract][Full Text] [Related]
45.
Armstrong JM; Martin CR; Dechet C; Morton K; Evans D; Ambrose J; Maughan BL; O'Neil B; Lowrance W
Urol Oncol; 2020 Jul; 38(7):636.e1-636.e6. PubMed ID: 32317221
[TBL] [Abstract][Full Text] [Related]
46. Impact of 18F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy.
Payne H; Bomanji J; Bottomley D; Scarsbrook AF; Teoh EJ;
Nucl Med Commun; 2022 Feb; 43(2):201-211. PubMed ID: 34669678
[TBL] [Abstract][Full Text] [Related]
47. A review discussing fluciclovine (
Zanoni L; Bossert I; Matti A; Schiavina R; Pultrone C; Fanti S; Nanni C
Future Oncol; 2018 May; 14(11):1101-1115. PubMed ID: 29359581
[TBL] [Abstract][Full Text] [Related]
48. Clinical impact of
Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
[TBL] [Abstract][Full Text] [Related]
49. Impact of
Andriole GL; Scarsbrook AF; Savir-Baruch B;
Urol Oncol; 2023 Jun; 41(6):293.e1-293.e7. PubMed ID: 37121865
[TBL] [Abstract][Full Text] [Related]
50. Best Practices for
Tade FI; Sajdak RA; Gabriel M; Wagner RH; Savir-Baruch B
J Nucl Med Technol; 2019 Dec; 47(4):282-287. PubMed ID: 31182661
[No Abstract] [Full Text] [Related]
51. Prostate Cancer Imaging with 18F-Fluciclovine.
Savir-Baruch B; Schuster DM
PET Clin; 2022 Oct; 17(4):607-620. PubMed ID: 36229104
[TBL] [Abstract][Full Text] [Related]
52. The role of
Kim SJ; Lee SW
Clin Radiol; 2019 Nov; 74(11):886-892. PubMed ID: 31358294
[TBL] [Abstract][Full Text] [Related]
53. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.
Nanni C; Schiavina R; Brunocilla E; Borghesi M; Ambrosini V; Zanoni L; Gentile G; Vagnoni V; Romagnoli D; Martorana G; Fanti S
Clin Genitourin Cancer; 2014 Apr; 12(2):106-10. PubMed ID: 24135632
[TBL] [Abstract][Full Text] [Related]
54. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
55. Review of
Gusman M; Aminsharifi JA; Peacock JG; Anderson SB; Clemenshaw MN; Banks KP
Radiographics; 2019; 39(3):822-841. PubMed ID: 31059396
[TBL] [Abstract][Full Text] [Related]
56.
Abiodun-Ojo OA; Akintayo AA; Akin-Akintayo OO; Tade FI; Nieh PT; Master VA; Alemozaffar M; Osunkoya AO; Goodman MM; Fei B; Schuster DM
J Nucl Med; 2019 Nov; 60(11):1531-1536. PubMed ID: 30954940
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.
Chau A; Gardiner P; Colletti PM; Jadvar H
Clin Nucl Med; 2018 Jul; 43(7):e226-e231. PubMed ID: 29762238
[TBL] [Abstract][Full Text] [Related]
58. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
[TBL] [Abstract][Full Text] [Related]
59. A PET/MRI study towards finding the optimal [
Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):695-703. PubMed ID: 27817158
[TBL] [Abstract][Full Text] [Related]
60. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
